These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 33774140)

  • 1. The Net Benefit of a treatment should take the correlation between benefits and harms into account.
    Buyse M; Saad ED; Peron J; Chiem JC; De Backer M; Cantagallo E; Ciani O
    J Clin Epidemiol; 2021 Sep; 137():148-158. PubMed ID: 33774140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: A simulation study.
    Giai J; Maucort-Boulch D; Ozenne B; Chiêm JC; Buyse M; Péron J
    Stat Med; 2021 Feb; 40(3):553-565. PubMed ID: 33140505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of correlations between prioritized outcomes on the net benefit and its estimate by generalized pairwise comparisons.
    Fuyama K; Ogawa M; Mizusawa J; Kanemitsu Y; Fujita S; Kawahara T; Sakamaki K; Oba K
    Stat Med; 2023 May; 42(10):1606-1624. PubMed ID: 36849124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of a clinical trial using generalized pairwise comparisons to test a less intensive treatment regimen.
    Backer M; Sengar M; Mathews V; Salvaggio S; Deltuvaite-Thomas V; Chiêm JC; Saad ED; Buyse M
    Clin Trials; 2024 Apr; 21(2):180-188. PubMed ID: 37877379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restricted Net Treatment Benefit in oncology.
    Piffoux M; Ozenne B; De Backer M; Buyse M; Chiem JC; Péron J
    J Clin Epidemiol; 2024 Jun; 170():111340. PubMed ID: 38570079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generalized pairwise comparison methods to analyze (non)prioritized composite endpoints.
    Verbeeck J; Spitzer E; de Vries T; van Es GA; Anderson WN; Van Mieghem NM; Leon MB; Molenberghs G; Tijssen J
    Stat Med; 2019 Dec; 38(30):5641-5656. PubMed ID: 31659790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generalized pairwise comparisons of prioritized outcomes are a powerful and patient-centric analysis of multi-domain scores.
    Deltuvaite-Thomas V; De Backer M; Parker S; Deneux M; Polgreen LE; O'Neill C; Salvaggio S; Buyse M
    Orphanet J Rare Dis; 2023 Oct; 18(1):321. PubMed ID: 37828533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence synthesis analysis with prioritized benefit outcomes in oncology clinical trials.
    Cui Y; Dong G; Kuan PF; Huang B
    J Biopharm Stat; 2023 May; 33(3):272-288. PubMed ID: 36343174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generalized Pairwise Comparisons to Assess Treatment Effects: JACC Review Topic of the Week.
    Verbeeck J; De Backer M; Verwerft J; Salvaggio S; Valgimigli M; Vranckx P; Buyse M; Brunner E
    J Am Coll Cardiol; 2023 Sep; 82(13):1360-1372. PubMed ID: 37730293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Operational characteristics of generalized pairwise comparisons for hierarchically ordered endpoints.
    Deltuvaite-Thomas V; Burzykowski T
    Pharm Stat; 2022 Jan; 21(1):122-132. PubMed ID: 34346169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized Net Benefit estimation and meta-analysis using generalized pairwise comparisons in N-of-1 trials.
    Giai J; Péron J; Roustit M; Cracowski JL; Roy P; Ozenne B; Buyse M; Maucort-Boulch D
    Stat Med; 2023 Jan; ():. PubMed ID: 36597195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injected corticosteroids for treating plantar heel pain in adults.
    David JA; Sankarapandian V; Christopher PR; Chatterjee A; Macaden AS
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD009348. PubMed ID: 28602048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring.
    Péron J; Buyse M; Ozenne B; Roche L; Roy P
    Stat Methods Med Res; 2018 Apr; 27(4):1230-1239. PubMed ID: 27487842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial.
    Evans SR; Knutsson M; Amarenco P; Albers GW; Bath PM; Denison H; Ladenvall P; Jonasson J; Easton JD; Minematsu K; Molina CA; Wang Y; Wong KL; Johnston SC
    Clin Trials; 2020 Dec; 17(6):617-626. PubMed ID: 32666831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The number needed to treat for net effect (NNTnet) as a metric for measuring combined benefits and harms.
    Li G; Lip GYH; Marcucci M; Thabane L; Tian J; Levine MAH
    J Clin Epidemiol; 2020 Sep; 125():100-107. PubMed ID: 32512185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.
    Péron J; Roy P; Ozenne B; Roche L; Buyse M
    JAMA Oncol; 2016 Jul; 2(7):901-5. PubMed ID: 27124210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial factorial trials: comparing methods for statistical analysis and economic evaluation.
    Dakin HA; Gray AM; MacLennan GS; Morris RW; Murray DW
    Trials; 2018 Aug; 19(1):442. PubMed ID: 30115104
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.